TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06226168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and environmental conditions
Description: Participants will perform endurance-strength training for 4 weeks in a variety of environmental conditions. Somatic indices and quantitative indicators of bone mass (bone mineral density) will be measured both before and after the training period. Before the first training day and the day after the last training day, blood will be drawn for biochemical analysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and environmental conditions
Description: Participants will perform endurance-strength training for 4 weeks in a variety of environmental conditions. Somatic indices and quantitative indicators of bone mass (bone mineral density) will be measured both before and after the training period. Before the first training day and the day after the last training day, blood will be drawn for biochemical analysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and environmental conditions
Description: Passive exposure to normobaric hypoxia conditions. No training intervention. There will be a measurement of selected somatic indices and a quantitative measurement of bone mass indices (bone mineral density). A blood draw for biochemical analysis will be performed.
Study: NCT04695028

Intervention type: OTHER
Intervention: Data collection
Description: The following data will be collected by the physician: sociodemographic profile, clinical manifestations, comorbidities, laboratory tests,etc.~Diagnostic performance of different imagery techniques, performance of crystal deposit quantification in ultrasound and Dual-energy computed tomography (DECT), link between co-morbidities and volume of baseline crystal deposits then during monitoring, link between co-morbidities (including cardiovascular events and new diagnoses of co-morbidity) and vascular baseline crystal deposits and during follow-up, link between microcrystalline rheumatism activity and the quantity of crystal deposits in baseline imaging and during follow-up, link between co-morbidities and the evolution of microcrystalline baseline rheumatism and then during follow-up, link between co-morbidities and the evolution of crystal deposition volumes, the concordance of the evaluation of uratic stocks and their evolution between the imagery means.
Study: NCT02223416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGB-10

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Study: NCT06283732

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Greens powder
Description: Participants are to consume one scoop (8.5 g) of the greens powder mixed in 8-10 oz of water every morning before breakfast for two weeks.
Study: NCT06206798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resourcefulness Group
Description: The content of the Resourcefulness intervention group includes 6 sessions such as session 1 to introduce resourcefulness skills; sessions 2-4 to discuss personal resourcefulness skills including planning daily activities, and positive self-talk; sessions 4-5 to discuss social resourcefulness skills including relying on family or friends, and seeking professional assistance.
Study: NCT06550427

Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA analyzed by phased variant
Description: this observational cohort study is to investigate the correlation between ctDNA analyzed by phased variant and the early outcome of the disease.
Study: NCT03926520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy (ECT)
Description: Stimulus method of delivery will be RUL electrode placement, and ultra-brief (UB) pulse width (0.25-0.37ms). At the first ECT session, seizure threshold (ST) will be determined by titration with the empirical dose titration method and subsequent treatments will be approximately 6 times the ST. Following other NIMH sponsored multicenter ECT studies (PRIDE, U01 MH055495), stimulus settings will be adjusted as needed during the ECT course based on seizure quality and treatment efficacy. Participants will be administered anesthesia.
Study: NCT04526847

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent energy restriction (IER) : 5:2 diet pattern
Description: Participants in the IER group will be provided menus on fasting day that provide \~25% of the individual energy requirement (400 kcal/day for females and 600 kcal/day for males) that means \~75% energy restriction per week (Sundfør et al., 2018; Svendsen, 2018; Templeman, Gonzalez, Thompson, \& Betts, 2020). The recommended fasting day may be on two non-consecutive days (Mondays and Thursdays) per week and remaining five days of the week will be based on the usual diet plan. All participants will be instructed to complete all food by 12 pm and then fast until 8 am the following day (Svendsen, 2018).Thus, the weekly average calorie intake will correspond to \~75% of the normal energy requirements. They will receive a diet plan that recommended \~50 gm protein/day from chicken breast, lean meat, lean fish, fat-free yogurt, cottage cheese, egg or legumes, and vegetables to increase satiety on fasting days.
Study: NCT06373783

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subepithelial connective tissue graft
Description: The area where the gingival recession occurred was prepared with the modified coronally positioned flap technique developed by Zuchelli. The subepithelial connective tissue graft was obtained in each patient using the single incision technique from the region between the mesial of the canine and the mesial of the first molar in the palate. Connective tissue dimensions were approximately 10x5x2 mm. The graft thickness was measured with an endodontic spreader from 3 points (mesial, buccal, and distal) and an electronic caliper during surgery.
Study: NCT04526847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (IER) : 5:2 diet pattern
Description: Participants in the IER group will be provided menus on fasting day that provide \~25% of the individual energy requirement (400 kcal/day for females and 600 kcal/day for males) that means \~75% energy restriction per week (Sundfør et al., 2018; Svendsen, 2018; Templeman, Gonzalez, Thompson, \& Betts, 2020). The recommended fasting day may be on two non-consecutive days (Mondays and Thursdays) per week and remaining five days of the week will be based on the usual diet plan. All participants will be instructed to complete all food by 12 pm and then fast until 8 am the following day (Svendsen, 2018).Thus, the weekly average calorie intake will correspond to \~75% of the normal energy requirements. They will receive a diet plan that recommended \~50 gm protein/day from chicken breast, lean meat, lean fish, fat-free yogurt, cottage cheese, egg or legumes, and vegetables to increase satiety on fasting days.
Study: NCT06373783

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: de- epithelize gingival graft
Description: The area where the gingival recession occurred was prepared with the modified coronally positioned flap technique developed by Zuchelli. A shallow horizontal incision was made at ≈3 mm apical from the gingival margin of the maxillary molar teeth using a number 15 scalpel blade. Subsequently, a parallel horizontal incision, at ≈ 4 mm apical from the first horizontal incision, was traced in conjunction with two vertical releasing incisions to delineate a rectangular area. Then, the uppermost epithelial layer was scraped off using a size 11 scalpel tip. The connective tissue graft to be taken from the palate area was 10x5x2 mm in size, and the graft thickness was measured with an endodontic spreader from 3 points (mesial, buccal, and distal) and electronic caliper during surgery.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonography
Description: Clinical parameter measurements (probing depth (PD), clinical attachment level (CAL), gingival recession depth and width, keratinized tissue width and height) were taken on the day of surgery, the 3rd days, the 14th days, the 1st month, the 3rd months and the 6th months.~Ultrasonography measurements A 6-18 MHz intraoral probe was used in intraoral USG examinations. Sterile gel was applied to the intraoral probe and covered with a stretch film. Then, it was placed directly on the mucosal surface of the receiver site in the buccal area. Mucosal thickness was evaluated using the B-mode of the device, and vascularization was evaluated using the color doppler and pulsed wave doppler modes of the device. The following equation is used and calculated by US unit pulsatility index (PI) = (Vmax-Vmin) (Vmean) (Vmax is peak systolic flow velocity. Vmin is diastolic flow velocity and Vmean is mean flow velocity.) The mean PI values of each patient were measured.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonography
Description: Clinical parameter measurements (probing depth (PD), clinical attachment level (CAL), gingival recession depth and width, keratinized tissue width and height) were taken on the day of surgery, the 3rd days, the 14th days, the 1st month, the 3rd months and the 6th months.~Ultrasonography measurements A 6-18 MHz intraoral probe was used in intraoral USG examinations. Sterile gel was applied to the intraoral probe and covered with a stretch film. Then, it was placed directly on the mucosal surface of the receiver site in the buccal area. Mucosal thickness was evaluated using the B-mode of the device, and vascularization was evaluated using the color doppler and pulsed wave doppler modes of the device. The following equation is used and calculated by US unit pulsatility index (PI) = (Vmax-Vmin) (Vmean) (Vmax is peak systolic flow velocity. Vmin is diastolic flow velocity and Vmean is mean flow velocity.) The mean PI values of each patient were measured.
Study: NCT05300841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dydrogesterone 20 mg /d (Duphaston, Abott Healthcare , Egypt)
Description: Pretreatment with dydrogestrone (Duphaston, Abott Healthcare, Egypt) will be administered during the cycle preceding the ICSI cycle in a daily dose of 20 mg/ day starting 10 days before the presumed onset of menses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dydrogesterone 20 mg /d (Duphaston, Abott Healthcare , Egypt)
Description: Pretreatment with dydrogestrone (Duphaston, Abott Healthcare, Egypt) will be administered during the cycle preceding the ICSI cycle in a daily dose of 20 mg/ day starting 10 days before the presumed onset of menses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol valerate 2 mg /d (white tablets of cycloprognova, Bayer Shering, Germany)
Description: will receive dydrogestrone 10mg /day plus estradiol valerate 2 mg /d (white tablets of cycloprognova, Bayer Schering, Germany) for 10 days.
Study: NCT05517902

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: StrataGraft
Description: StrataGraft® Construct
Study: NCT05748366

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus Anterior Plane Block (SAPB)
Description: The ultrasound-guided serratus anterior plane block (SAPB) will be performed in a manner previously described in published medical literature. Patients will be consented and monitored. Bupivacaine 0.5% (5 mg/ml) diluted to 30-40 ml will be used in a dose not to exceed 2 mg/kg. The serratus anterior fascial plane will be identified in the 4th/5th intercostal space. The needle will be advanced under real-time ultrasound guidance targeting the superficial serratus anterior fascial plane. The procedure assistant will inject small volumes to hydrodissect the muscle bellies evenly under direct visualization, indicating local anesthetic spread within the fascial plane. Anesthetic will then be injected in 5 ml increments and the needle will be removed. Patient will be continuously monitored on telemetry and pulse-oximetry. Reassessment of the patient will continue for 30 minutes to monitor for signs of local anesthetic systemic toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Analgesic Medications
Description: Analgesic medications will be administered via the intravenous, intramuscular or oral route at the discretion of the medical treatment team.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Analgesic Medications
Description: Analgesic medications will be administered via the intravenous, intramuscular or oral route at the discretion of the medical treatment team.
Study: NCT04526847

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous energy restricted (CER) group
Description: Participants in the CER group will be advised to reduce total energy intake to 1200-1550 kcal in all seven days a week. They will be provided diet plan calculated in relation to each person's estimated energy requirements. Menus will be divided into breakfast, lunch, dinner, and snacks in line with their individualized energy recommendations. They will be requested to consume \~75% of the individual energy requirements daily (25% energy restriction of calculated baseline energy requirements daily) over six months. Thus, the overall energy restriction will similar between the groups at an estimated reduction of 25% of requirements. Participants will be randomized in a 1:1 ratio, and assigned to an intermittent or continuous energy restriction group randomly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous energy restricted (CER) group
Description: Participants in the CER group will be advised to reduce total energy intake to 1200-1550 kcal in all seven days a week. They will be provided diet plan calculated in relation to each person's estimated energy requirements. Menus will be divided into breakfast, lunch, dinner, and snacks in line with their individualized energy recommendations. They will be requested to consume \~75% of the individual energy requirements daily (25% energy restriction of calculated baseline energy requirements daily) over six months. Thus, the overall energy restriction will similar between the groups at an estimated reduction of 25% of requirements. Participants will be randomized in a 1:1 ratio, and assigned to an intermittent or continuous energy restriction group randomly.
Study: NCT06235827

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tean group
Description: Patients in Group A will have to consume two cups (250ml for each cup) of hot green tea, five days per week for 6 months. A tea bag is brewed in 250ml hot water for 3 minutes. They are only allowed to consume as hot drink, not for iced tea. Any sweetener or sugar is not allowed to mix in the drink. The green tea bag will be distributed to patient at beginning of research and at every visit. Patient will be reminded weekly using text messages or phone call by a research assistant for green tea consumption.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control group
Description: Patients in Group B will not be consuming green tea during 6 months of study period.
Study: NCT04723225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cat-Cow Yoga
Description: Cat-Cow is one of the essential postures in yoga for its beneficial reasons. It is an alternate shift of posture from flexion of the back (rounded) to the extension of the back (arched). During each set of movement, inhalation and exhalation will be guided
Study: NCT04941937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs. Selinexor 60mg/d QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs. Selinexor 60mg/d QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs. Selinexor 60mg/d QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100mg/d, Po. on day1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: PO,Lenalidomide 25mg once daily from D1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle, PO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).
Study: NCT05911438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Derisomaltose Injection (Monoferric) and Human Erythropoietin Injection (EPIAO)
Description: Ferric Derisomaltose Injection (Monoferric): 1000 mg, intravenous infusion 6±2 days before surgery; Human Erythropoietin Injection (EPIAO): 36000 IU, subcutaneous injection 6±2 days before surgery and 3±1 days after surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Basic Treatment
Description: Daily energy intake of 20-30 kcal/kg, with fat accounting for 20-30% of total energy; Iron: ≥15 mg/d, protein intake of 1.2-1.5 g/kg/d; Simultaneously enhance functional exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Treatment
Description: Daily energy intake of 20-30 kcal/kg, with fat accounting for 20-30% of total energy; Iron: ≥15 mg/d, protein intake of 1.2-1.5 g/kg/d; Simultaneously enhance functional exercises.
Study: NCT05741450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens 1 (monthly replacement)
Description: Monthly replacement spherical silicone hydrogel contact lens for 15 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens 2 (daily disposable)
Description: Daily disposable spherical silicone hydrogel contact lens for 15 minutes
Study: NCT05764057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin propanediol (FORXIGA™/FARXIGA™1)
Description: Dapagliflozin (10 mg per day; per os) on top of standard of care as recommended in current guidelines\* for 6 months (experimental group)~\*All patients will receive optimal medical therapy (including antithrombotic, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blocker or sacubitril/valsartan, diuretics, antagonists of the mineralocorticoid receptor) according to their clinical condition as recommended.
Study: NCT06270251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBIT
Description: 8sessions of CBIT following a published treatment manual delivered over 10 weeks (the last two sessions are biweekly)~CBIT is a well-established behavioral treatment that is considered by the American Academy of Neurology to be the first-line intervention for tics.
Study: NCT05586672

Intervention type: DEVICE
Intervention: EEG-HR
Description: Passation EEG-HR

Intervention type: DEVICE
Intervention: EEG-HR
Description: Passation EEG-HR

Intervention type: DIAGNOSTIC_TEST
Intervention: ADI-R
Description: Passation of ADI-R scale
Study: NCT06365957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketone monoester supplementation
Description: Exogenous ketones are a class of ketone bodies that are ingested using nutritional supplements or foods. This class of ketone bodies refers to the three water-soluble ketones (acetoacetate, β-hydroxybutyrate, and acetone).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketone monoester supplementation
Description: Exogenous ketones are a class of ketone bodies that are ingested using nutritional supplements or foods. This class of ketone bodies refers to the three water-soluble ketones (acetoacetate, β-hydroxybutyrate, and acetone).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketone monoester supplementation
Description: Exogenous ketones are a class of ketone bodies that are ingested using nutritional supplements or foods. This class of ketone bodies refers to the three water-soluble ketones (acetoacetate, β-hydroxybutyrate, and acetone).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise
Description: High-intensity interval exercise is a type of interval training exercise. It incorporates several rounds that alternate between several minutes of high-intensity movements to significantly increase the heart rate to at least 80% of one's maximum heart rate, followed by short periods of lower-intensity movements. The exercise will be conducted on a computer-monitored cycle ergometer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise
Description: High-intensity interval exercise is a type of interval training exercise. It incorporates several rounds that alternate between several minutes of high-intensity movements to significantly increase the heart rate to at least 80% of one's maximum heart rate, followed by short periods of lower-intensity movements. The exercise will be conducted on a computer-monitored cycle ergometer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous exercise
Description: Moderate-intensity continuous exercise generally consists of 30-60 min of aerobic exercise at 64-76% peak heart rate, while interval training involves more intense bouts interspersed by recovery periods. The exercise will be conducted on a computer-monitored cycle ergometer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous exercise
Description: Moderate-intensity continuous exercise generally consists of 30-60 min of aerobic exercise at 64-76% peak heart rate, while interval training involves more intense bouts interspersed by recovery periods. The exercise will be conducted on a computer-monitored cycle ergometer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo will be the taste-matched water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo will be the taste-matched water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo will be the taste-matched water.